Rozanolixizumab (Rystiggo) (AChR-positive and MuSKR-positive gMG) Company: UCB Clinical trial(s): MycarinG (Stage 3 complete) More Information NICE status: First committee meeting 14/8/24 MHRA status: Approved Learn more about rozanolixizumab. Manage Cookie Preferences